CardieX (ASX:CDX) has announced progress with its China growth strategy by establishing a business operations and marketing presence in Beijing and Shanghai.
The company said the launch of China operations follows regulatory approval in that country of the Oscar 2 with 'SphygmoCor Inside' Ambulatory Blood Pressure Monitor (ABPM).
This is the product of a collaboration between CardieX's wholly owned group company, AtCor Medical, and leading US-based blood pressure monitor manufacturer, SunTech Medical.
Chinese regulatory approval allows Oscar 2 with SphygmoCor to be utilised by over 20,000 physicians, hospitals and clinics throughout China where ABPM is the most effective method of detection, diagnosis, monitoring and management of hypertension – one of the greatest public health disorders in China.
The company said the launch of the Oscar 2 builds on recent steps forward in China for CardieX group company inHealth. Its telehealth solutions will be deployed across China’s third-largest telemedicine platform, Health160, which has over 167 million registered users across the country.
CardieX said it and inHealth are also looking into further opportunities to supply inHealth’s telehealth solutions and home health devices onto other telemedicine platforms in China.
CardieX said it has also been moving forward to grow its local operations in China. It said initial hires for CardieX’s China operations are in place and focused on local operations, business development, and clinical marketing.
According to CardieX CEO, Craig Cooper, “China represents an enormous market opportunity for CardieX, and we have already seen strong demand for our telemedicine programs and Oscar 2 with SphygmoCor technology. This is an exciting period for CardieX. We have already made significant progress establishing our China operations, and the company is going from strength to strength. We are hitting the ground running, and we expect to announce further significant updates on our China operations shortly.”